Mental disorders have a high prevalence compared with many other health conditions and are the leading cause of disability worldwide. Several studies performed in the last years support the involvement of the endocannabinoid system in the etiopathogenesis of different mental disorders. The present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. We will focus on the findings from human brain studies regarding alterations in endocannabinoid levels, cannabinoid receptors and endocannabinoid metabolizing enzymes in patients suffering mental disorders. Studies carried out in humans have consistently demonstrated that the endocannabinoid system is fundamental for emotional homeostasis and cognitive function. Thus, deregulation of the different elements that are part of the endocannabinoid system may contribute to the pathophysiology of several mental disorders. However, the results reported are controversial. In this sense, different alterations in gene and/or protein expression of CB1 receptors have been shown depending on the technical approach used or the brain region studied. Despite the current discrepancies regarding cannabinoid receptors changes in depression and schizophrenia, present findings point to the endocannabinoid system as a pivotal neuromodulatory pathway relevant in the pathophysiology of mental disorders.
Depression is the most prevalent of the mental illnesses and serotonin (5-hydroxytryptamine, 5-HT) is considered to be the major neurotransmitter involved in its etiology and treatment. In this context, 5-HT1A receptors have attracted interest as targets for therapeutic intervention. Notably the activation of presynaptic 5-HT1A autoreceptors delays antidepressant effects whereas the stimulation of postsynaptic 5-HT1A heteroreceptors is needed for an antidepressant action. NLX-101 (also known as F15599) is a selective biased agonist which exhibits preferred activation of cortical over brain stem 5-HT1A receptors. Here, we used behavioral, neurochemical and molecular methods to examine the antidepressant-like effects in rats of a single dose of NLX-101 (0.16 mg/kg, i.p.). NLX-101 reduced immobility in the forced swim test when measured 30 min but not 24 h after drug administration. NLX-101 increased extracellular concentrations of glutamate and dopamine in the medial prefrontal cortex, but no changes were detected in the efflux of noradrenaline or 5-HT. NLX-101 also produced an increase in the activation of pmTOR, pERK1/2 and pAkt, and the expression of PSD95 and GluA1, which may contribute to its rapid antidepressant action.
Major depressive disorder (MDD) is a complex neuropsychiatric disorder affected by genetic and environmental factors and associated with inflammation and impaired neuroplasticity. This study investigated the role of matrix metalloproteinase-9 (MMP-9), inflammatory markers (STAT3 and NF-κB), and the neuroplasticity marker BDNF in the prefrontal cortex of subjects with MDD and their matched controls. The results showed increased MMP-9 expression and activity in MDD, particularly in those without detectable antidepressant treatment and in subjects who died by suicide. The association with suicide was especially pronounced in women, suggesting sex-dependent differences. Regarding inflammation, untreated subjects showed higher STAT3 and NF-κB levels, while antidepressant-treated subjects showed reduced STAT3 levels, particularly men, suggesting a possible anti-inflammatory effect of antidepressants. In addition, treated men showed higher BDNF levels, which may reflect enhanced neuroplasticity. Overall, this study suggests that MMP-9 may be a potential marker of depression severity and suicidal behavior, especially in women, while neuroinflammation may play a more prominent role in men. These findings further highlight the importance of considering sex differences when investigating the role of MMP-9 in the pathophysiology of MDD.